StockData

IRulya Therapeutics Inc. (IRLA) income statement

IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$39.88−0.06 (-0.15%)

Close on Nov 20, 2026Market cap $40.56MP/E –Yield –

See a number that looks wrong?